| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9937132 | DUCHESNAY | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
Feb, 2033
(9 years from now) | |
| US9375404 | DUCHESNAY | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
Feb, 2033
(9 years from now) | |
| US9526703 | DUCHESNAY | Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
Feb, 2033
(9 years from now) | |
| US9089489 | DUCHESNAY | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
Feb, 2033
(9 years from now) | |
Bonjesta is owned by Duchesnay.
Bonjesta contains Doxylamine Succinate; Pyridoxine Hydrochloride.
Bonjesta has a total of 4 drug patents out of which 0 drug patents have expired.
Bonjesta was authorised for market use on 07 November, 2016.
Bonjesta is available in tablet, extended release;oral dosage forms.
Bonjesta can be used as treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.
The generics of Bonjesta are possible to be released after 18 February, 2033.
Drugs and Companies using DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 November, 2016
Treatment: Treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management
Dosage: TABLET, EXTENDED RELEASE;ORAL
BONJESTA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic